Preview

Российский кардиологический журнал

Расширенный поиск

Влияние базовой терапии на частоту повторных госпитализаций по поводу декомпенсации сердечной недостаточности: возможности и ограничения в современной клинической практике

https://doi.org/10.15829/1560-4071-2021-4699

Полный текст:

Аннотация

В настоящем обзоре рассматривается клиническое и эпидемиологическое значение госпитализаций по поводу декомпенсации сердечной недостаточности, а также особенности использования указанных событий в качестве показателя эффективности проводимой терапии. Приведены данные о частоте применения препаратов, снижающих риск госпитализаций, в рандомизированных клинических исследованиях и в реальной практике. Обсуждаются причины недостаточно частого назначения препаратов для лечения сердечной недостаточности со сниженной фракцией выброса и использования их в недостаточно высоких дозах, к которым относятся терапевтическая инертность и физиологические ограничения и необходимость внедрения в клиническую практику препаратов с альтернативными механизмами действия.

Об авторе

С. Р. Гиляревский
Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия

Доктор медицинских наук, профессор, профессор, профессор кафедры клинической фармакологии и терапии

Москва



Список литературы

1. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468-75. doi:10.1056/NEJM199111213252103.

2. Packer M, Pitt B, Rouleau JL, et al. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. JACC Heart Fail. 2017;5(6):399-407. doi:10.1016/j.jchf.2017.03.003.

3. Fiuzat M, Lowy N, Stockbridge N, et al. Endpoints in Heart Failure Drug Development: History and Future. JACC Heart Fail. 2020;8(6):429-40. doi:10.1016/j.jchf.2019.12.011.

4. Goenka L, George M, Selvarajan S. End points in heart failure-are we doing it right? Eur J Clin Pharmacol. 2017;73(6):651-9. doi:10.1007/s00228-017-2228-0.

5. Solomon SD, Dobson J, Pocock S, et al; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-7. doi:10.1161/CIRCULATIONAHA.107.696906.

6. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260-6. doi:10.1016/j.ahj.2007.01.041.

7. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001. Erratum in: J Am Coll Cardiol. 2020;75(1):132.

8. Collins SP, Pang PS, Lindsell CJ, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12:1253-60. doi:10.1093/eurjhf/hfq133.

9. Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15(10):1082-94. doi:10.1093/eurjhf/hft095.

10. Blair JE, Zannad F, Konstam MA, et al; EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008;52(20):1640-8. doi:10.1016/j.jacc.2008.07.056.

11. Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail. 2014;2(3):289-97. doi:10.1016/j.jchf.2013.12.007.

12. Ponikowski P, Kirwan BA, Anker SD, et al; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-904. doi:10.1016/S0140-6736(20)32339-4.

13. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/NEJMoa2022190.

14. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167:1493-502. doi:10.1001/archinte.167.14.1493.

15. Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076-84. doi:10.1093/eurjhf/hfq154.

16. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA. 2010;303:2141-7. doi:10.1001/jama.2010.748.

17. Adams KFJr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. doi:10.1016/j.ahj.2004.08.005.

18. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and out- comes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011;37:619-26. doi:10.1007/s00134-010-2113-0.

19. Eapen Z, Reed S, Yanhong L, et al. Do countries or hospitals with longer stays have lower readmission rates? Findings from the ASCEND-HF trial. Circ Heart Fail. 2013;6(4):727-32. doi:10.1161/CIRCHEARTFAILURE.112.000265.

20. Sato N, Kajimoto K, Asai K, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159:949-55. doi:10.1016/j.ahj.2010.03.019.

21. Fonarow GC, Abraham WT, Albert NM, et al. Day of admission and clinical outcomes for patients hospitalized for heart failure: findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Circ Heart Fail. 2008;1(1):50-7. doi:10.1161/CIRCHEARTFAILURE.107.748376.

22. Bhatt DL, Szarek M, Steg PG, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-28. doi:10.1056/NEJMoa2030183.

23. Anker SD, McMurray JJ. Time to move on from ‘time-to-first’: should all events be included in the analysis of clinical trials? Eur Heart J. 2012;33:2764-5. doi:10.1093/eurheartj/ehs277.

24. Rogers JK, McMurray JJ, Pocock SJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012;126(19):2317-23. doi:10.1161/CIRCULATIONAHA.112.110536.

25. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33:176-2. doi:10.1093/eurheartj/ehr352.

26. Rogers JK, Pocock SJ, McMurray JJ, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014;16(1):33-40. doi:10.1002/ejhf.29. Erratum in: Eur J Heart Fail. 2014;16(5):592.

27. Borer JS, Böhm M, Ford I, et al; SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813-20. doi:10.1093/eurheartj/ehs259.

28. Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol. 2009;53(24):2248-58. doi:10.1016/j.jacc.2008.12.079.

29. Ariti CA, Cleland JG, Pocock SJ, et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2011;162(5):900-6. doi:10.1016/j.ahj.2011.08.003.

30. Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circ Heart Fail. 2021;14(4):e008335. doi:10.1161/CIRCHEARTFAILURE.121.008335.

31. Butler J, Yang M, Manzi MA, et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(8):935-44. doi:10.1016/j.jacc.2018.11.049.

32. Butt JH, Fosbøl EL, Gerds TA, et al. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. Eur J Heart Fail. 2020;22(10):1777-85. doi:10.1002/ejhf.1800.

33. Фомин И.В. Хроническая сердечная недостаточность в российской федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi:10.15829/1560-4071-2016-8-7-13.

34. Greene SJ, Fonarow GC, Butler J. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. Circ Heart Fail. 2020;13(6):e007132. doi:10.1161/CIRCHEARTFAILURE.120.007132.

35. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. doi:10.1016/S0140-6736(99)04440-2.

36. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. doi:10.1056/NEJM198706043162301.

37. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. doi:10.1016/S0140-6736(98)11181-9.

38. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8. doi:10.1056/NEJM200105313442201.

39. Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492.

40. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.

41. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.

42. Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. 2020. Ahead of print. doi:10.1007/s10741-020-09979-z.

43. Crespo-Leiro MG, Segovia-Cubero J, González-Costello J, et al; project research team. Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry. Rev Esp Cardiol (Engl Ed). 2015;68(9):785-93. doi:10.1016/j.rec.2015.03.008.

44. Komajda M, Anker SD, Cowie MR, et al. Physicians' adher- ence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514-22. doi:10.1002/ejhf.510.

45. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351-66. doi:10.1016/j.jacc.2018.04.070.

46. Brunner-La Rocca HP, Linssen GC, Smeele FJ, et al., Investigators C-H. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry. JACC Heart Fail. 2019;7(1):13-21. doi:10.1016/j.jchf.2018.10.010.

47. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585-96. doi:10.1161/CIRCULATIONAHA.109.934471.

48. Linssen GCM, Veenis JF, Brunner-La Rocca HP, et al; CHECK-HF investigators. Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry. Neth Heart J. 2020;28(6):334-44. doi:10.1007/s12471-020-01421-1.

49. Maggioni AP, Dahlström U, Filippatos G, et al.; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. doi:10.1093/eurjhf/hft050.

50. Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(suppl 11):S212-20.

51. Savarese G, Xu H, Trevisan M, et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail. 2019;7(1):65-76. doi:10.1016/j.jchf.2018.10.003.

52. Rossignol P, Ménard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58(19):1958-66. doi:10.1016/j.jacc.2011.04.049.

53. Nordberg Backelin C, Fu M, Ljungman C. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Fail. 2020;7(3):1049-55. doi:10.1002/ehf2.12644.

54. O'Connor PJ, Sperl-Hillen JM, Johnson PE, et al., editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

55. Aujoulat I, Jacquemin P, Rietzschel E, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract 2014;5:141-7. doi:10.2147/AMEP.S59022.

56. Jarjour M, Henri C, de Denus S, et al. Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? JACC Heart Fail. 2020;8(9):725-38. doi:10.1016/j.jchf.2020.04.019.

57. Honigberg MC, Vardeny O, Vaduganathan M. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. Circ Heart Fail. 2020;13(2):e006623. doi:10.1161/CIRCHEARTFAILURE.119.006623.


Для цитирования:


Гиляревский С.Р. Влияние базовой терапии на частоту повторных госпитализаций по поводу декомпенсации сердечной недостаточности: возможности и ограничения в современной клинической практике. Российский кардиологический журнал. 2021;26(10):4699. https://doi.org/10.15829/1560-4071-2021-4699

For citation:


Gilyarevsky S.R. Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. Russian Journal of Cardiology. 2021;26(10):4699. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4699

Просмотров: 103


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)